The only FDA-approved equine PSGAG

As the only FDA-approved equine PSGAG (polysulfated glycosaminoglycan) for degenerative joint disease (DJD) in horses, Adequan® i.m. actually treats degenerative joint disease (DJD), not just its clinical signs.1,2 For over 30 years, Adequan® i.m. has been administered by veterinarians to help horses of every discipline and level enjoy greater mobility over their lifetimes.1,3,4

Horse running in stable

INDICATIONS

Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here .

How To Use Graph How To Use Graph

Treat the disease, not just the clinical signs of DJD

Adequan® i.m. is unlike any other equine joint product. It’s been proven to work in multiple ways to maintain joint function:3,4

  • Reduce inflammation
  • Restore synovial joint lubrication
  • Repair joint cartilage
  • Reverse the disease process

The benefits of
1•4•7 dosing

When administered at the recommended label dose, Adequan® i.m. not only reaches joints quickly, but also helps to protect and renew joint mobility.1,3

Their powerful beauty moves us to make a difference

Every day, we’re inspired by the athleticism, heart and devotion of horses
– whether it’s a top athlete in world-class competition or a backyard companion on a daily ride. Their partnership and companionship are like nothing else. It’s why we support equine events, organizations and associations who share our commitment to these amazing animals.

INDICATIONS
Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here .
1. Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.
2. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
3. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
4. Adequan® i.m. Package Insert, Rev 1/19.

Let’s stay in touch

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

EQUINE VETERINARY
PROFESSIONAL 		HORSE OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up
MORE ABOUT ADEQUAN
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
Animal Health Logo
All trademarks are the property of American Regent, Inc.
©2022, American Regent, Inc.
PP-AI-US-0268 (v4.0) 01/2022